Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 4, n° 2
pages 152-159 (février 1981)
Doi : 10.1016/S0190-9622(81)70018-5
Clinical and laboratory studies

Pyoderma gangrenosum treated with clofazimine : Report of three cases
 

Elizabeth C. Kark, M.D. , 1, Bryan R. Davis, M.D. 1, Jerome R. Pomeranz, M.D. 1
Cleveland, OH, USA 

*Reprint requests to: Dr. Elizabeth C. Kark, Kaiser Permanente Medical Center, 12301 Snow Road, Parma OH 44130/216-362-2301.
@@#100979@@

Three cases of pyoderma gangrenosum (PG) responsive to clofazimine are reported. The ulcers were recalcitrant to other forms of therapy, and the patients were incapacitated. Healing began within 2 or 3 weeks. To our knowledge, these are the first reported cases of PG responsive to clofazimine in the United States.

The full text of this article is available in PDF format.
1  From the Division of Dermatology, Department of Medicine, Cleveland Metropolitan General Hospital and Case Western Reserve University School of Medicine.

Top of the page

© 1981  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@